This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ThousandOaks- and Shanghai-based ThousandOaks Biopharmaceuticals , a new contract manufacturing organization fort he biotech industry, said it has received $45M in a Series A financing round. The company's Chairman is Shun Luo, Ph.D.,
ThousandOaks-based wireless hardware provider Xirrus has raised yet another $10M in funding, according to a regulatory filing from the company Monday. Xirrus develops specialized, Wi-Fi hotspots specifically aimed at high density and high performance installations, such as campuses and public areas. Venture Partners.
ThousandOaks-based biopharmaceuticals startup Atara Biotherapeutics announced this morning that it has raised $38.5M in a Series B funding round, for its efforts to develop treatments for patients with end-stage renal disease. atara biotherapeutics venture capital renal disease lifescience amgen' READ MORE>>.
ThousandOaks-based biotech giant Amgen said Monday afternoon that it is acquiring Biovex , a Woburn, Massachusetts-based developer of treatments for melanoma and head and neck cancer. BioVex develops OncoVEX, a novel oncolytic vaccine in Phase 3 clinical development. READ MORE>>.
ThousandOaks-based biotech giant Amgen has backed a developer of therapeutic antibodies, via its venture capital arm, Amgen Ventures. Theraclone is developing therapeutic antibodies for treating infectious disease and cancer. READ MORE>>.
Xirrus , the wireless hardware provider based in ThousandOaks, has just raised $10.1M Xirrus, which is backed by August Capital, Canaan Partners, InterWest Partners, QuestMark Partners, and US Venture Partners, last announced a funding round back in September. in a funding round, part of an ongoing $11.0M
ThousandOaks-based biotech giant Amgen said this morning that it has agreed to buy KAI Pharmaceuticals , a developer of treatments for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis, for $315M in cash. KAI Pharmaceuticals is based in South San Francisco. READ MORE>>.
ThousandOaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. immungene venture capital biotech biotechnology cancer therapeutics' READ MORE>>.
Amgen Ventures , the venture capital arm of ThousandOaks-based Amgen , has re-upped on an investment in a biopharmaceuticals developing microRNA-based treatments for cardiovascular and muscle disease. and Broadview Ventures. miRagen is based in Boulder, Colorado.
ThousandOaks-based Ceres , a developer of biofuel crop technology, has raised another $20M in funding, according to a regulatory filing from the firm Friday. Tags: warburg capital venture clean cleantech energy biofuel ceres. Source of the new funding was not disclosed. READ MORE>>.
ThousandOaks-based Atara Biotherapeutics announced this morning that it is in a second close of its Series B funding round, bringing its total raised in the funding to $52M. Atara is developing a number of biotherapeutics, including a treatment for protein energy wasting (PEW) and a treatment for ovarian cancer and other solid tumors.
ThousandOaks-based Xirrus , the developer of high speed, high performance wireless networking hardware, has raised another big chunk of financing, saying today that it has raised $23.5M in a Series E funding round. Xirrus said the funding will go towards sales growth and its product.
Amgen Ventures , the venture capital arm of ThousandOaks-based Amgen , has backed the developer of a biopharmaceutical aimed at treating irritable bowel syndrome, kidney disease, and diabetes.
San Diego-based Ocean Aero , a developer of unmanned, autonomous marine vehicles, has scored funding from ThousandOaks-based Teledyne , the companies said this morning. investment strategic capital venture marine ocean ship robot autonomous robotic oceanaero aero' Financial terms of the investment were not disclosed.
ThousandOaks-based Xirrus , a developer of Wi-Fi networking hardware, has raised another $20M in funding, according to a regulatory filing from the firm today. Xirrus has previously raised funding from US Venture Partners, August Capital, Canaan Partners, and QuestMark Partners. READ MORE>>.
ThousandOaks-based Nexsan , a developer of data storage systems, has delayed its IPO, according to its underwriter, Thomas Weisel Partners. The firm's IPO was being underwritten by Thomas Weisel Partners, Lazard Capital Markets, Needham & Company, and Morgan Keegan & Company.
The venture capital arm of ThousandOaks-based Amgen has placed more funding into one of its portfolio companies, Sutro Biopharma , which is working on developing a scalable biochemical protein synthesis platform aimed at cancer therapeutics. Sutro said it has raised $16.5M
ThousandOaks-based Ceres , a developer of biofuels crop technology, said Thursday that it has completed a private offering of convertible preferred stock. Ceres is developing improved seed varieties--including. Tags: ceres venture capital biotech lifescience biofuel energy cleantech clean crop seed. READ MORE>>.
ThousandOaks-based Ceres , the developer of specialized seeds for the biofuels market, has priced its IPO, saying that it will offer up 5,000,000 shares of its common stock at $13.00 Barclays Capital, PIper Jaffray, Raymond James, and Simmons & Company International.
ThousandOaks-based Ceres , the developer of seeds aimed at producing renewable, biomass feedstocks for the biofuels industry, has filed for an IPO. and Barclays Capital. and Barclays Capital. The firm's IPO is being underwritten by Goldman, Sachs & co., The firm said it had a net loss of $22.5M READ MORE>>.
ThousandOaks-based Xirrus , the venture backed developer of Wi-Fi equipment headed by Dirk Gates, said today that it has deployed its products at the Madison School District in Rexburg, Idaho. Xirrus is venture backed by August Capital, Canaan Partners, InterWest, QuestMark Partners, and US Venture Partners.
ThousandOaks-based Ceres , a developer of biofuel crop technology, and Novozymes , a developer of enzymes, said today that the two have entered into a research collaboration around cellulosic biofuel production. Financial details of the partnership were not disclosed.
ThousandOaks-based Ceres , the developer of seeds to supply the bioenergy and biofuels feedstock business, has set its initial pricing range for its IPO, according to a filing from the company this morning. Barclays Capital, Piper Jaffray, Raymond James, and Simmons & Company International. and $23.00
ThousandOaks-based Xirrus confirmed Tuesday that it has raised an additional $20M in funding, bringing the firm's total raised to $80M. Xirrus is a developer of Wi-Fi networking hardware, which combines a number of Wi-Fi access points and switching in a single device. The round was led by InterWest Partners. READ MORE>>.
ThousandOaks-based Ceres , the developer of seed stock for energy crops, said today that it has closed its IPO, selling a total of 5,750,000 shares of its common stock at $13.00 Barclays Capital, Piper Jaffray, Raymond James, and Simmons & Company International. The firm is now trading around $15.08. READ MORE>>.
ThousandOaks-based Xirrus , a developer of Wi-Fi networking hardware, has scored another education customer, the firm announced today. Xirrus develops Wi-Fi equipment which combines multiple wireless access points and switching, to provide better coverage and higher bandwidth to wireless deployments. READ MORE>>.
ThousandOaks-based Xirrus , which develops Wi-Fi networking devices, reported today that it has deployed its Wi-Fi arrays at the Corona-Norco Unified School District. The firm is backed by August Capital, Canaan Partners, Interwest, QuestMark, and U.S. Financial impact of the win was not disclosed. READ MORE>>.
ThousandOaks-based drug development company Atara Biotherapeutics announced this morning that it has added Matthew K. Fust as a board member, and hired Mitchall G. Clark as its Chief Regulatory and Quality Assurance Officer. READ MORE>>. atara biotherapeutics renal disease lifescience amgen executive board'
ThousandOaks-based Xirrus has rolled out a new Wi-Fi array, the firm said earlier this week, the Xirrux XN8. Xirrus develops switched wireless Wi-Fi hardware which combines multiple Wi-Fi access points in a single piece of hardware. Pricing of the new hardware was not released. READ MORE>>
Amgen Ventures , the venture investment arm of ThousandOaks-based Amgen , is one of the new investors in precision oncology and medicine startup Syapse. READ MORE>>.
ThousandOaks-based Capsida Biotherapeutics, a new biotechnology company focused on using adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases, has uncloaked from stealth mode, saying it has raised $140M in total capital.
ThousandOaks-based Amgen is the lead investor in a round for San Francisco- and Bozeman, Montana-based SiteOne Therapeutics , SiteOne said on Friday. SiteOne said it raised $15M in a Series B funding round, which was led b Amgen, and also included Next Frontier Capital and insiders.
ThousandOaks-based Amgen has made another investment this morning in immunology startup Tizona Therapeutics , via its venture capital arm, Amgen Ventures. Series A investors--including Amgen Ventures--also participated, with investments from MPM Capital, Astellas Venture Management and InterWest Partners. READ MORE>>.
Amgen Ventures , the venture capital arm of ThousandOaks-based Amgen , is one of the investors in a Boston biotech company, Akili Interactive. Akili is developing digital medicine products aimed at treating cognitive dysfunction, including ADHD, multiple sclerosis, and depression. READ MORE>>.
ThousandOaks-based Amgen has returned as one of the investors in cancer therapeutis developer Sutro Biopharma , as part of an $85.4M Sutro Biopharma is developing a piepline of cancer therapeutics, with the lead contact targeted at treating lymphoma and multiple myeloma. funding round. in a Series E funding round.
ThousandOaks-based Amgen has seen an exit out of its startup investment portfolio, and activities of its Amgen Ventures venture capital arm, at Berkeley-based Adheron Therapeutics this morning. Adheron said that it has been acquired by Roche , in a deal worth $105M upfront and up to $475M in additional milestone payments.
ThousandOaks-based biotech giant Amgen is the a new investor in a round for Alector , a developer of immuno-modulatory therapies for Alzheimer's disease and other neurogenerative disorders, which announced a $29.5M funding today. READ MORE>>.
ThousandOaks-based Akriveia Therapeutics , a biotechnology startup focused on immuno-oncology, announced this morning that it has raised $7.5M The investment came from F-Prime Capital Partners. in a Series A investment.
ThousandOaks-based wireless hardware provider Xirrus has scored a customer win in Australia, the firm disclosed this morning. Xirrus develops equipment which combines Wi-Fi access points with Ethernet switching, which enables better coverage, bandwidth, and performance for wireless connections. READ MORE>>.
ThousandOaks-based Xirrus, a developer of Wi-Fi network hardware, announced today that the firm's products have been deployed at a university in Russia. Xirrus is backed by August Capital, Canaan Partners, QuestMark Partners, and US Venture Partners, and is headed by Dirk Gates, former founder of Xircom. READ MORE>>.
ThousandOaks-based Amgen and Swiss biotech company Molecular Partners AG said Tuesday that the two are in a collaboration and licensing deal, for the commercialization of a molecule aimed at the immuno-oncology area. READ MORE>>.
ThousandOaks-based Xirrus , a developer of Wi-Fi networking equipment, announced Monday that it has put together a portable, pre-packaged kit which is designed for deploying Wi-Fi into disaster response and temporary events. Venture Partners, August Capital, and QuestMark Partners. READ MORE>>.
ThousandOaks-based Teledyne Technologies has increased its stake in San Diego-based Ocean Aero , a developer of unmanned, robotic underwater and surface vehicles used for the scientific, defense, and oil and gas market, the company said late Friday. Financial terms of the deal were not disclosed.
ThousandOaks-based Dantari has raised $47M in its Series A funding, saying that it has launched a new, clinical-stage biotechnology company developing targeted therapeutics for the treatment of cancers and other diseases.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content